Our RNA Services platform supports pharmaceutical, biotechnology, and advanced therapy companies in accelerating RNA-based drug development from early discovery to preclinical and CMC readiness. We provide integrated solutions covering mRNA, saRNA, circRNA, siRNA, and antisense oligonucleotide (ASO) programs, with a focus on scalability, regulatory alignment, and translational feasibility. Designed for enterprise clients, our RNA CDMO and research services emphasize robust process development, analytical rigor, and manufacturability to meet global regulatory expectations.
Scalable Manufacturing: Transitioning RNA candidates from research scale to process-ready material requires reproducible IVT systems, impurity control strategies, and scalable purification workflows. We support process optimization with an emphasis on consistency and downstream GMP readiness.
Delivery & Stability: RNA therapeutics face intrinsic instability and delivery barriers. Our services address formulation screening, LNP compatibility assessment, and stability evaluation to improve in vivo performance while maintaining manufacturability.
Quality & Regulatory Alignment: RNA products must meet increasing global regulatory expectations for impurity profiling, residual DNA control, dsRNA reduction, and analytical characterization. We design analytical strategies aligned with IND-enabling requirements to support enterprise regulatory pathways.
Sequence & Structural Optimization: Effective RNA therapeutics require codon optimization, UTR engineering, structural evaluation, and immunogenicity risk assessment. Our multidisciplinary team integrates bioinformatics and experimental validation to enhance translational potential.
Our end-to-end RNA services are designed to support biotechnology companies, pharmaceutical developers, and research institutions throughout the entire RNA project lifecycle. From sequence design and RNA production to formulation support and analytical characterization, we provide integrated technical services that help streamline experimental workflows and reduce coordination between multiple vendors.
By combining RNA engineering, scalable synthesis technologies, and comprehensive analytical support, our platform enables researchers to efficiently advance RNA-based research programs and technical development projects.
A structured overview of RNA modality support, manufacturing readiness, and typical enterprise applications. This matrix is designed to help biotechnology and pharmaceutical partners evaluate scalability, modification flexibility, and translational feasibility across RNA platforms under current industry standards.
| RNA Type | Typical Practical Length Range | Modification Support | Manufacturing Readiness | Typical Enterprise Use Case |
| mRNA | ~0.5–10 kb (project-dependent) | Broad (cap strategy, nucleoside modification, poly(A) control) | Research → Preclinical → GMP (widely established) | Vaccines, protein replacement, oncology and rare disease programs |
| saRNA | ~7–15 kb (platform-dependent) | Selective (size and replicase constraints apply) | Research/Preclinical common; GMP requires platform maturity | Dose-sparing vaccines, durable antigen expression strategies |
| circRNA | ~0.5–5 kb (process-dependent) | Case-by-case (circularization chemistry dependent) | Research/Preclinical common; GMP dependent on analytics readiness | Extended expression, repeat-dosing therapeutic strategies |
| siRNA | ~19–23 bp duplex | Broad (2' modifications, backbone stabilization, conjugation-ready) | Research → Preclinical → GMP (well-established globally) | Gene silencing, liver-targeted programs, metabolic & genetic diseases |
| ASO | ~12–25 nt | Broad (PS backbone, 2' modifications, gapmer designs) | Research → Preclinical → GMP (mature platform) | Splice modulation, CNS and rare disease indications |
| gRNA/sgRNA | ~60–200 nt | Common stability-focused modifications | Research/Preclinical common; GMP depends on editing strategy | CRISPR gene editing, ex vivo cell therapy workflows |
Analytical rigor is central to regulatory success and product consistency. The following matrix outlines key characterization capabilities aligned with current IND-enabling and GMP expectations across major regulatory regions.
| Analytical Category | Development Objective | Typical Methods | Applicable Modalities | Stage Alignment |
| Identity & Sequence Confirmation | Confirms molecular identity and supports comparability | Sequencing, LC-MS mapping (as appropriate) | All RNA modalities | Discovery → GMP |
| Purity & Impurity Profiling | Detects truncations, byproducts, and synthesis residuals | HPLC/UPLC, CE, electrophoretic methods | All RNA modalities | Preclinical → GMP |
| Integrity / Size Distribution | Ensures transcript stability and lot consistency | Fragment analysis, CE, gel-based systems | mRNA, saRNA, circRNA | Discovery → GMP |
| dsRNA Monitoring | Supports immunogenicity risk mitigation | Immunoassay-based detection, chromatography strategies | IVT-derived RNAs | Preclinical → GMP |
| Residual DNA Control | Ensures removal of template-related contaminants | qPCR-based quantification | Template-derived RNA products | Preclinical → GMP |
| Capping / 5' End Characterization | Correlates cap structure with translational performance | Enzymatic assays, HPLC/LC-MS approaches | mRNA/saRNA | Discovery → GMP |
| Potency / Expression Assays | Demonstrates biological activity aligned with MOA | Cell-based assays, reporter systems, ELISA/qPCR | All therapeutic RNA types | Discovery → Preclinical |
Delivery strategy selection directly impacts translational success. This compatibility overview supports early development planning by aligning RNA modality with commonly adopted in vivo and ex vivo delivery approaches in the current global market.
| RNA Format | LNP | Polymer / Liposome | Conjugate / Targeted Delivery | Electroporation / Ex Vivo |
| mRNA | Common and clinically validated | Program-dependent | Emerging strategies | Widely used in cell engineering |
| saRNA | Common (size-sensitive optimization required) | Case-dependent | Limited but evolving | Feasible in controlled settings |
| circRNA | Common | Case-dependent | Emerging | Feasible |
| siRNA | Common | Common | Common (ligand-conjugate approaches) | Used in research/ex vivo workflows |
| ASO | Less common | Case-dependent | Common targeted strategies | Common in research settings |
| gRNA/sgRNA | Program-dependent | Case-dependent | Limited | Widely used for CRISPR ex vivo editing |
This workflow reflects how enterprise teams typically engage RNA service partners for project execution, quality control, and milestone delivery. It is designed for technical services across RNA synthesis, formulation support, and analytical characterization—supporting research through IND-enabling readiness.
Define modality (mRNA/saRNA/circRNA/siRNA/ASO/gRNA), target use (research, preclinical, GMP-ready), target product profile expectations, timelines, and confidentiality requirements. Establish a clear scope, deliverables, and acceptance criteria.
Conduct a feasibility review covering sequence complexity, modification needs, expected scale, delivery/formulation constraints, and analytics requirements. Finalize the project plan, risk register, and sample/data handoff format.
Establish design inputs and process routes: template strategy (if applicable), synthesis/IVT parameters, capping/poly(A) plans, purification route, and preliminary specifications. For oligonucleotides, confirm chemistry/modification approach and purification targets.
Execute production runs (RNA synthesis/IVT and purification) with in-process checks for yield, integrity, and key attributes. Adjust parameters using predefined change-control logic to maintain reproducibility and meet acceptance criteria.
For programs requiring delivery feasibility, conduct formulation compatibility work (e.g., LNP feasibility and attribute profiling) and stability planning (buffer screening, storage condition assessment) to support downstream development.
Complete agreed analytical panels (identity/purity/integrity, impurity monitoring, and formulated product attributes where applicable). Deliver COA-style outputs, methods summary, batch records (as applicable), and a data package to support internal decision gates and regulatory documentation.
Our RNA service platform is designed to support biotechnology companies, pharmaceutical developers, and research institutions requiring reliable RNA production, analytical characterization, and technical development support. The focus is on reproducibility, scalability, and compatibility with real-world research and development workflows.
RNA technologies are widely used across many areas of biomedical research and biotechnology innovation. Our technical services support researchers working in diverse experimental settings where RNA molecules are used as tools for gene expression, gene regulation, genome editing, and biological pathway investigation.
RNA molecules such as siRNA, antisense oligonucleotides, and guide RNAs are widely used to study gene function, gene knockdown effects, and regulatory pathways in cellular and molecular biology research.
mRNA-based systems are frequently applied to transiently express proteins in mammalian cells for experimental studies, protein engineering, and cellular reprogramming workflows.
Guide RNAs and related RNA components are essential tools for CRISPR-based genome editing studies, enabling precise gene modification experiments in cell-based systems.
RNA constructs such as circRNA, modified mRNA, and structured RNAs are used to investigate RNA stability, translation efficiency, RNA-protein interactions, and post-transcriptional regulation.
Researchers developing delivery systems such as lipid nanoparticles, polymer carriers, or conjugate strategies often require well-characterized RNA materials for formulation and delivery optimization studies.
RNA materials are commonly used in proof-of-concept studies, biomarker validation experiments, and early translational research aimed at evaluating new biological targets and experimental therapeutic strategies.
Whether you require RNA synthesis, analytical characterization, formulation feasibility assessment, or custom technical development support, our team provides structured RNA services designed for biotechnology companies, pharmaceutical developers, and research institutions. Our specialists work closely with clients to define project scope, recommend appropriate technical strategies, and deliver RNA materials and analytical data aligned with research and preclinical program requirements. Contact us to discuss your RNA service needs and explore how our platform can support your next research or development milestone.
We provide end-to-end RNA services including RNA design, synthesis (IVT and chemical), purification, modification, formulation support, and analytical characterization. Our platform supports multiple RNA types such as mRNA, saRNA, circRNA, siRNA, ASO, and guide RNA.
End-to-end RNA services typically cover the full workflow from sequence design and template preparation to RNA production, purification, modification (e.g., capping or nucleotide modification), formulation support, and analytical testing. This integrated approach reduces the need for multiple vendors and improves project efficiency.
IVT (in vitro transcription) is typically used for longer RNA molecules such as mRNA, saRNA, and circRNA, while chemical synthesis is used for shorter RNAs like siRNA, ASO, and guide RNA. The choice depends on RNA length, structure, and application requirements.
Commonly synthesized RNA types include mRNA, saRNA, circRNA, siRNA, antisense oligonucleotides (ASO), and CRISPR guide RNAs. Each type requires different synthesis and processing strategies.
Common RNA modifications include 5' capping, poly(A) tail addition, and nucleotide modifications. These can improve RNA stability, translation efficiency, or experimental performance depending on the application.
